www.fdanews.com/articles/184113-fda-approves-new-diabetes-drug-formulation-for-astrazenaca
FDA Approves New Diabetes Drug Formulation for AstraZenaca
October 25, 2017
The FDA approved a new formulation of AstraZenaca’s type-2 diabetes treatment Bydureon, the company said.
The approval includes administration by a modified once-weekly, single-dose autoinjector device, the company said.
Bydureon is indicated for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise.